So the only thing standing in the way of BOT's human trials is ethics approval, they received ethics approval very quickly for the Permetrex safety studies done last year so you'd think this would be a mere formality now.
Given the hype in the sector, once these human trials start with synthetic CBP expect media and public interest to skyrocket.
The market still catching up to how far ahead of the curve BOT really are from the other hopefuls.
Ann: Export and Import Approvals for Clinical Studies Received, page-6
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
14.5¢ |
Change
-0.005(3.33%) |
Mkt cap ! $289.2M | |||
| Open | High | Low | Value | Volume |
| 15.0¢ | 15.3¢ | 14.0¢ | $2.578M | 17.58M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 34 | 1328056 | 14.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 15.0¢ | 2256202 | 31 |
View Market Depth
| Last trade - 15.19pm 01/08/2025 (20 minute delay) ? |
| BOT (ASX) Chart |